H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Aquestive Therapeutics to $7 from $6 and keeps a Buy rating on the shares following the Q4 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AQST:
- Aquestive Therapeutics price target raised to $8 from $3 at Lake Street
- Aquestive Therapeutics Updates Investors with Presentation and Financials
- Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
- Aquestive Therapeutics options imply 25.7% move in share price post-earnings
- Options Volatility and Implied Earnings Moves Today, March 05, 2024